CENTENNIAL, Colo., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Acesis Holdings Corporation (“Acesis Biomed”), a pre‑clinical stage biotechnology company pioneering oral treatments for metabolic and endocrine disorders linked to low testosterone in men, today announced the appointment of Dr. Frederic Fasano, Pharm.D, MBA, ICD.D, to its Board of Directors. Dr. Fasano is a veteran pharmaceutical and biotech executive with over 30 years... Read More

MONTREAL , Feb. 6, 2025 /CNW/ - Valeo Pharma Inc. (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it has closed a share purchase agreement (the " Transaction ") with Xediton Pharmaceuticals Inc. (" Xediton " or the " Purchaser ") in its proceedings under the Companies' Creditors Arrangement Act (the " CCAA "). As part of its CCAA proceedings, the Company implemented a Court-supervised... Read More

MONTREAL , Oct. 1, 2024 /CNW/ - Valeo Pharma In c. (TSX: VPH) (FSE: VP2), a Canadian pharmaceutical company, announced today that the Québec Superior Court (Commercial Division) (the " Court ") has issued an initial order (the " Initial Order ") granting the Company and its subsidiaries VPI Pharmaceuticals Inc. / VPI Pharmaceutiques Inc. and Valeo Pharma Corp. (collectively, the " Company " or " Valeo ") protection under the... Read More

Q3-24 revenues of $12.6 million , down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23 Q3-24 adjusted EBITDA loss of $1.5 million compared to $2.5 million for Q3-23, down 40% MONTREAL , Sept. 12, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today reported its financial results for the... Read More

MONTREAL , Sept. 9, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2024 on Thursday September 12, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday September 13,... Read More

MONTREAL , Sept. 3, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the " Amendment ") with Sagard Healthcare Royalty Partners, LP (" Sagard "), which amends the Secured Term Loan (the " Facility '') entered into between Valeo and Sagard in July 2022. The Facility is amended to provide, among other... Read More

MONTREAL , Aug. 29, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that the Company is voluntarily delisting its Class A shares from trading on the OTCQB Venture Market due to low trading volume, the associated administrative requirements and costs and other corporate and commercial priorities. The Company's last day of... Read More

MONTREAL , Aug. 6, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that the Company's Chief Development Officer, Mr. Al Moghaddam , has been appointed to succeed retiring CEO Steve Saviuk . Mr. Saviuk will remain on Valeo's Board of Directors and assume the role of Chairman. Mr. Richard J. MacKay will step down from his... Read More

MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer ("CDO") and consequently he is stepping down from the Company's Board of Directors. As Valeo's new CDO, Mr. Moghaddam will lead the design and implementation of... Read More

Record Q2-24 revenues of $14.1 million , up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million for Q2-23, up 48% Total Enerzair and Atectura prescriptions for the 12 months ending April 30, 2024 , exceeded 88,000, up 96% over the 12 months ending April 30, 2023 MONTREAL , June 13, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF)... Read More

Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exceeding $2 million Restructuring charges to be incurred in Q3-24 Cost reduction initiatives are aimed at improving margins, significantly reducing operating expenses to accelerate path to profitability MONTREAL , June 13, 2024 /CNW/ Valeo Pharma ( TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("... Read More

MONTREAL , June 4, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2024 on Thursday June 13, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday June 14, 2024 at... Read More

MONTREAL , April 9, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Steve Saviuk , Valeo's Chief Executive Officer, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from... Read More

MONTREAL , March 22, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has joined the Company's Board of Directors. "We are very pleased to welcome Mr. Moghaddam to the Valeo Board of Directors. He is a seasoned and recognized senior pharmaceutical executive with a long track record of superior... Read More

Q1-24 revenues of $13.5 million , up 3% over Q1-23 Q1-24 adjusted EBITDA loss of $2.1 million compared to $2.2 million for Q1-23, down 6% Total Enerzair and Atectura prescriptions for the 12 months ending January 31, 2024 , exceeded 78,000, up 130% over the 12 months ending January 31, 2023 MONTREAL , March 14, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian... Read More

MONTREAL , March 7, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2024 on Thursday March 14, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Friday March 15, 2024 at... Read More

MONTREAL , Feb. 13, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Messrs. Robert Raich and Charles Bisaillon have joined the Company's Board of Directors and that Messrs. Michel Trudeau , Stuart Fowler , Didier Leconte and Ms. Tamara Close have all resigned from its Board of Directors. "We are pleased to welcome... Read More

Original commercialization and supply agreement amended following global divestment of XIIDRA® SIMBRINZA® remains under Valeo Pharma exclusive promotion and distribution Proceeds from reimbursement to be used for debt reduction purposes Sagard credit facility amended to provide for early repayments and liquidity requirements in fiscal 2024 MONTREAL , Feb. 2, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:... Read More

Record revenues of $54 million for fiscal 2023, up 94% over 2022 Revenues of $13.1 million for Q4-23, up 4% over Q4-22 Record annual adjusted gross profit of $16.9 million for 2023, compared to $9.4 million for 2022, up 80% 2023 adjusted EBITDA loss of $10.9 million compared to $14.5 million for 2022, down 25% Total Enerzair and Atectura prescriptions for the 12 months ending October 31, 2023 , exceeded 67,000, up 179% over... Read More

MONTREAL , Jan. 22, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2023 on Monday January 29, 2024 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday... Read More

Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share details about recent executive changes within the company. Saviuk announced the appointment of Pascal Tougas as the new chief financial officer, succeeding Luc Mainville. Tougas is recognized as a well-experienced senior executive in the pharmaceutical industry, with a robust financial background. His previous tenure at Sanofi Canada for 11 years saw... Read More

Costs reduction initiatives and organizational realignment expected to generate annual savings exceeding $2 million . MONTREAL , Nov. 20, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that it has undertaken a series of initiatives to reduce operating costs and drive operational efficiency as it moves toward... Read More

MONTREAL , Nov. 7, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Mr. Richard Lajoie has joined the Company's Board of Directors and that Ms. Maureen C. Brennan has retired from its Board of Directors "We are pleased to welcome Richard to the Valeo Board of Directors. His extensive and diverse pharmaceutical industry... Read More

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe and Mail's Report on Business annual list of Canada’s top-growing companies. The company placed 151 out of 425, with a three-year growth rate of 322%. Saviuk explained that the rankings are calculated on revenue growth, and the exponential growth in the company's Enerzair asthma... Read More

MONTREAL , Oct. 4, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, is pleased to announce it placed No. 151 on the 2023 Report on Business ranking of Canada's Top Growing Companies. Canada's Top Growing Companies ranks Canadian companies on three-year revenue growth. Valeo placed 151 st out of 425 companies that earned a spot in this... Read More

MONTREAL , Sept. 27, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it has entered into a credit facility agreement with Accord Financial Inc. The $5 million credit facility is secured by a first rank lien on the Corporation's short term assets, and bears interest at the Scotiabank's prime rate plus an applicable... Read More

MONTREAL , Sept. 7, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2023 on Wednesday September 13, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Thursday September 14,... Read More

$3.92 million raised from non-brokered private placement offering, and $0.58 million from insider loan Investissement Québec and insiders each invest $2.0 million Proceeds from the financing to be used to strengthen working capital and support ongoing growth MONTREAL , Aug. 31, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today... Read More

MONTREAL , June 22, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the appointment of Ms. Close and Mr. Leconte, Valeo's Board of Directors is now comprised of 8 Directors, 5 of whom are independent. "We are pleased to welcome... Read More

MONTREAL , June 7, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on Tuesday June 13, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday June 14, 2023 at... Read More

Q2-23 revenues to exceed $13.5 million Q2-23 adjusted EBITDA loss to decrease below $2.0 million Q2-23 operating expenses to remain in line with prior quarters ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year MONTREAL , May 25, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today provided a financial and commercial... Read More

MONTREAL , April 28, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on April 27, 2023 (the " Meeting "). Election of Directors The results of the vote for those elected as directors are as follows: Nominees Votes For Votes... Read More

MONTREAL , April 19, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that Steve Saviuk , Valeo's Chief Executive Officer, will present a corporate overview and provide a commercial update on key products of the Company at the 2023 Bloom Burton & Co Healthcare Investor Conference. Presentation Details: Event: 2023 Bloom... Read More

Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 Fifth consecutive quarter of adjusted gross profit increase at $4.2 million , up 178% over Q1-22 Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million , a 51% improvement over Q1-22 Physicians prescribing Enerzair and Atectura reached 1,583 at the end of Q1-23, representing 39% growth from the prior quarter and a... Read More

MONTREAL , March 9, 2023 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023 on Wednesday March 15, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Thursday March 16, 2023... Read More

Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson's patients in Quebec MONTREAL , Feb. 7, 2023 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Onstryv® (safinamide) for the treatment of patients suffering from Parkinson's disease, is now listed for public reimbursement on... Read More

In the final analysis of the Phase 3 cinical study conducted by Veru Inc., sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalized adult patients with moderate to severe COVID-19 who are at high risk for ARDS Sabizabulin also showed a significant reduction of days in ICU, days on mechanical ventilation and days in the hospital MONTREAL , Jan. 26, 2023 /CNW Telbec/ Valeo Pharma Inc . (TSX: VPH)... Read More

MONTREAL , Jan. 25, 2023 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the fourth quarter and year ended October 31, 2022 on Monday January 30, 2023 after market close. The Company will host a conference call to discuss those results and highlights on Tuesday... Read More

Valeo's President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of Directors MONTREAL , Nov. 21, 2022 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced that Mr. Frederic Fasano has stepped down as Valeo's President and Chief Operating Officer. Mr. Fasano will continue... Read More

In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for ARDS Sabizabulin also showed significant reduction of days in ICU, days on mechanical ventilation and days in the hospital Veru submitted a request for emergency use authorization to FDA in June 2022 Veru plans to request that... Read More

Record revenues of $6.1 million in Q3-22, a 27% increase over Q2-22 Record Gross Margins of $2.2 million in Q3-22, up 34% over Q2-22 Record YTD-22 revenues of $15.1 million , up 48% over YTD 2021 Q4-22 projected revenues to exceed $11 million XIIDRA®, SIMBRINZA® and ALLERJECT® to boost revenues starting Q4-22 Non-dilutive US $30 million financing from Sagard Healthcare Partners to accelerate growth Valeo Pharma Inc . (TSX:... Read More

Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022 on Tuesday September 13, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday September 14, 2022 at 8.30am (ET) . Conference... Read More

Kyle Steiger appointed Senior Vice-President and Chief Commercial Officer Jean-François Fournier appointed new Business Unit Head - Ophthalmology Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announced the appointment of Mr. Kyle Steiger to the role of Senior Vice-President and Chief Commercial Officer ("CCO"). Mr. Steiger is a pharmaceutical... Read More

Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand into Ophthalmology and Allergy Licensing transactions to more than double Valeo's annual revenues Provides financial flexibility to accelerate growth and reach profitability Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a growing Canadian pharmaceutical company, is... Read More

700,000 Canadians suffering from severe allergies Canadian epinephrine auto-injector market exceeds $80M annually ALLERJECT peak sales potential expected to exceed $25M annually Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a growing Canadian pharmaceutical company, announced today that it has entered into a License, Supply, and Commercialization agreement with Kaléo Inc. for the... Read More

Ophthalmology becomes additional strategic therapeutic area Significant market opportunities with more than 6 million 1 Canadians suffering from dry eye disease and 400,000 2 Canadians suffering from open-angle glaucoma or ocular hypertension Valeo to start recognizing revenues from XIIDRA ® and SIMBRINZA ® in Q4-22 Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian... Read More

Q2-22 revenues of $4.8 million , up 80% over Q2-21 Q2-22 gross margins of $1.7 million , up 134% over Q2-21 Canadian provincial public reimbursement now complete for Enerzair® Breezhaler® and Atectura® Breezhaler® with the addition of British Columbia and Newfoundland TSX listing of common shares and warrants Enerzair and Atectura demonstrating fast market penetration against established asthma brands Valeo Pharma Inc.... Read More

Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2022 on Tuesday June 14, 2022 after market close. The Company will host a conference call to discuss those results and highlights on Wednesday June 15, 2022 at 8.30am (ET) . Conference ID:... Read More

Valeo Pharma Inc . (TSX:VPH) (OTCQB: VPHIF) (FSE:VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today announces the results of the proposals submitted to shareholders at its annual meeting of shareholders held on April 27, 2022 (the " Meeting "). Proposal No. 1: Election of Directors The results of the vote for those elected as directors are as follows: Nominee Votes For Votes Withheld Number %... Read More

Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that Steve Saviuk , Valeo's Chief Executive Officer, will present a corporate overview and provide a commercial update on key products of the Company at the 2022 Bloom Burton & Co... Read More

Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, is pleased to announce that the 12% Convertible Unsecured Subordinated Debentures (the " Debentures ") issued pursuant to the $15.0 million bought deal private placement closed on December 9, 2021 , have... Read More

The Company's shares and warrants to start trading on March 29th, 2022 Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it has received final approval for the listing of its common shares and warrants on the Toronto Stock Exchange ("... Read More

Q1-22 revenues of $4.2 million , up 128% over Q1-21 Q1-22 gross margins of $1.4 million , up 266% over Q1-21 Public reimbursement secured in key provinces for Enerzair, Atectura and Redesca $25.0 million convertible debenture financing completed Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, today reported its financial results for the first quarter... Read More

Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia Enerzair Breezhaler and Atectura Breezhaler reimbursement also secured for Saskatchewan and Prince Edward Island Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian... Read More

Valeo Pharma Inc . (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2022 on Thursday March 24, 2022 after market close. The Company will host a conference call... Read More

Record revenues in 2021 of $13.6 million , up 81% over 2020 Annual Gross Margins for 2021, $4 Million , up 186% over 2020 Q4-21 revenues of $3.4 million , up 53% over Q4-20 Redesca®, Enerzair® Breezhaler® and Atectura® Breezhaler®, three transformational products launched during 2021, will help accelerate revenues and margins... Read More